PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA

FEBS Letters

Volumn 581, Issue 16, 2007, Pages 3098-3104

  Wang, Hongtao ^a   Zhang, Yan ^b,c   Heuckeroth, Robert O ^a  

^a Division of Gastroenterology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Extrahepatic cholestasis; Hepatocyte growth factor; Liver fibrosis; Matrix metalloproteinase; Plasminogen activator inhibitor 1; Tissue type plasminogen activator; Urokinase plasminogen activator

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BILE DUCT OBSTRUCTION; CHOLESTATIC LIVER FIBROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROGENESIS; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STELLATE CELL; WILD TYPE;

ANIMALS; BILE DUCTS; HEPATOCYTE GROWTH FACTOR; LIGATION; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA; MUS;

EID: 34250174207     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.05.049     Document Type: Article

References (35)

1. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
2. Wang H., Vohra B.P., Zhang Y., and Heuckeroth R.O. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 42 (2005) 1099-1108
3. Castellino F.J., and Ploplis V.A. Structure and function of the plasminogen/plasmin system. Thromb Haemostasis 93 (2005) 647-654
4. Dellas C., and Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb. Haemostasis 93 (2005) 631-640
5. Matsuo S., et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int. 67 (2005) 2221-2238
6. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D., and Simon R.H. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97 (1996) 232-237
7. Oda T., Jung Y.O., Kim H.S., Cai X., Lopez-Guisa J.M., Ikeda Y., and Eddy A.A. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 60 (2001) 587-596
8. Bergheim I., Guo L., Davis M.A., Duveau I., and Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther. 316 (2006) 592-600
9. Bataller R., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112 (2003) 1383-1394
10. Dooley S., Hamzavi J., Breitkopf K., Wiercinska E., Said H.M., Lorenzen J., Ten Dijke P., and Gressner A.M. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125 (2003) 178-191
11. Kaibori M., Inoue T., Oda M., Naka D., Rippe R.A., and Brenner D.A. The role of biologically active HGF. Hepatology 34 (2002) 475-481
12. Kaibori M., et al. Exogenously administered HGF activator augments liver regeneration through the production of biologically active HGF. Biochem. Biophys. Res. Commun. 290 (2002) 475-481
13. Tomita K., et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126 (2004) 873-885
14. Zhao B.Q., et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 103 (2004) 2610-2616
15. Menshikov M., Elizarova E., Plakida K., Timofeeva A., Khaspekov G., Beabealashvilli R., Bobik A., and Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem. J. 367 (2002) 833-839
16. Miranda-Diaz A., et al. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Mol. Ther. 9 (2004) 30-37
17. Gong R., Rifai A., Tolbert E.M., Centracchio J.N., and Dworkin L.D. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J. Am. Soc. Nephrol. 14 (2003) 3047-3060
18. Haruyama T., Ajioka I., Akaike T., and Watanabe Y. Regulation and significance of hepatocyte-derived matrix metalloproteinases in liver remodeling. Biochem. Biophys. Res. Commun. 272 (2000) 681-686
19. Bataller R., and Brenner D.A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 21 (2001) 437-451
20. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
21. Yee J.A., Yan L., Dominguez J.C., Allan E.H., and Martin T.J. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J. Cell Physiol. 157 (1993) 528-534
22. Khalil N., Corne S., Whitman C., and Yacyshyn H. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am. J. Respir. Cell Mol. Biol. 15 (1996) 252-259
23. Benyon R.C., and Arthur M.J. Mechanisms of hepatic fibrosis. J. Pediatr. Gastroenterol. Nutr. 27 (1998) 75-85
24. Ueno T., et al. OK-432 treatment increases matrix metalloproteinase-9 production and improves dimethylnitrosamine-induced liver cirrhosis in rats. Int. J. Mol. Med. 3 (1999) 497-503
25. Preaux A.M., Mallat A., Nhieu J.T., D'Ortho M.P., Hembry R.M., and Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 30 (1999) 944-950
26. Okamoto K., Mimura K., Murawaki Y., and Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastroenterol. Hepatol. 20 (2005) 1102-1108
27. Senties-Gomez M.D., Galvez-Gastelum F.J., Meza-Garcia E., and Armendariz-Borunda J. Hepatic fibrosis: role of matrix metalloproteases and TGFbeta. Gac. Med. Mex. 141 (2005) 315-322
28. Lin Y., et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int. 25 (2005) 796-807
29. Yamaguchi, I., Lopez-Guisa, J.M., Cai, X., Collins, S.J., Okamura, D.M. and Eddy, A.A. (in press). Endogenous urokinase lacks anti-fibrotic activity during progressive renal injury. Am. J. Physiol. Renal. Physiol.
30. Aoki N. Plasminogen activator inhibitor. Thromb. Res. 41 (2005) 455-464
31. Aoki N. The past, present and future of plasmin inhibitor. Thromb. Res. 116 (2005) 455-464
32. Hertig A., Berrou J., Allory Y., Breton L., Commo F., Costa De Beauregard M.A., Carmeliet P., and Rondeau E. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. Faseb J. 17 (2003) 1904-1906
33. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell. Sci. 116 (2003) 217-224
34. Salgado S., et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. 2 (2000) 545-551
35. Wang H., Zhang Y., and Heuckeroth R.O. Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice. Hepatology 45 (2007) 1527-1537